Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68382-0245-16 68382-0245 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
65597-0407-28 65597-0407 Pexidartinib hydrochloride Turalio 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Feb 1, 2023 In Use
62856-0710-30 62856-0710 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb 13, 2015 In Use
70710-1742-06 70710-1742 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00597-0138-95 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 8, 2013 In Use
00093-8231-28 00093-8231 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Dec 22, 2021 In Use
00069-0830-38 00069-0830 Sunitinib Malate Sutent 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Jul 12, 2014 In Use
70771-1395-08 70771-1395 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
70771-1903-06 70771-1903 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Apr 1, 2018 Jul 31, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
31722-0263-30 31722-0263 ERLOTINIB ERLOTINIB 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
42388-0023-36 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 16, 2017 In Use
43598-0045-63 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov 30, 2022 In Use
59651-0582-30 59651-0582 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Dec 4, 2024 In Use
63020-0040-12 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sep 15, 2021 Mar 31, 2025 In Use
00480-3237-51 00480-3237 Lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Dec 19, 2024 In Use
70710-1744-03 70710-1744 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
59651-0582-90 59651-0582 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Dec 4, 2024 In Use
60429-0926-30 60429-0926 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 30, 2016 In Use
63020-0040-90 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sep 15, 2021 Mar 31, 2025 In Use
81927-0201-01 81927-0201 Imatinib oral IMKELDI 80.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 19, 2024 In Use
72485-0217-30 72485-0217 Erlotinib hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 6, 2019 In Use
13668-0682-74 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Apr 12, 2023 In Use
57962-0014-28 57962-0014 Ibrutinib IMBRUVICA 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb 16, 2018 In Use

Found 11465 results — Export these results